Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Charles A DeRyke"'
Autor:
Amanda Azevedo Bittencourt, Gustavo Mizuno, Marina Della Negra de Paula, Charles Andrew DeRyke, Fakhar Siddiqui, Vinicius Lima Faustino, Paula de Mendonça Batista, Thales José Bueno Polis
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 27, Iss , Pp 102877- (2023)
Introdução: Pseudomonas aeruginosa com resistência a carbapenêmicos é um patógeno considerado prioritário (nível crítico) pela Organização Mundial da Saúde para o desenvolvimento de novos antimicrobianos. A resistência a antimicrobianos
Externí odkaz:
https://doaj.org/article/48798fe5f1f44e02a7aba4beefe55f25
Publikováno v:
Open Forum Infectious Diseases. 9
Background The Beta-Lactamase Inhibitors (BLIs) Relebactam (REL) and Avibactam (AVI) both inhibit class A and C beta-lactamases and are approved in combination with the beta-lactam antibiotics imipenem (IMI/REL) and ceftazidime (CAZ/AVI), respectivel
Autor:
Sibylle Lob, Meredith Hackel, Fakhar Siddiqui, Karri A Bauer, Charles A DeRyke, Katherine Young, Mary Motyl, Daniel F Sahm
Publikováno v:
Open Forum Infectious Diseases. 9
Background Antimicrobial resistance of P. aeruginosa to commonly used β-lactams is typically higher in isolates collected from ICU patients and those with hospital-acquired infections. P. aeruginosa with multidrug-resistance (MDR) or difficult-to-tr
Autor:
Sibylle Lob, Meredith Hackel, Fakhar Siddiqui, Karri A Bauer, Charles A DeRyke, Katherine Young, Mary Motyl, Daniel F Sahm
Publikováno v:
Open Forum Infectious Diseases. 9
Background Gram-negative pathogens with multidrug resistance (MDR) or difficult-to-treat resistance (DTR) are increasingly common, resulting in limited treatment options. These resistant pathogens are often isolated from the respiratory tract or bloo
Autor:
Aline Okuma, Thales Polis, Jacqueline Pavia, Gustavo Mizuno, Jacqueline Ferrari, Charles A DeRyke
Publikováno v:
Open Forum Infectious Diseases. 9
Background Pseudomonas aeruginosa (Pa) is a common cause of nosocomial pneumonia; resistance among traditionally used empiric agents is observed frequently. To improve patient outcomes, a heightened focus has been placed on evaluating the adequacy of
Autor:
Sibylle Lob, Meredith Hackel, Fakhar Siddiqui, Jacqueline Pavia, Charles A DeRyke, Katherine Young, Mary Motyl, Daniel F Sahm
Publikováno v:
Open Forum Infectious Diseases. 9
Background Ceftolozane is a cephalosporin specifically developed to have enhanced antibacterial activity against P. aeruginosa. Combined with tazobactam, it was approved by FDA and EMA for hospital-acquired/ventilator-associated bacterial pneumonia.
Publikováno v:
Infectious Diseases in Clinical Practice. 15:26-34
The Optimizing Pharmacodynamic Target Attainment using a Microbiology Antibiogram (OPTAMA) program aims to determine the likelihood that specific antibiotic regimens will achieve bactericidal pharmacodynamic exposures against common nosocomial pathog